Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II study of TYRA-300 in patients with pediatric achondroplasia

Next Previous
Trial Profile

A Randomized Phase II study of TYRA-300 in patients with pediatric achondroplasia

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TYRA-300 (Primary)
  • Indications Achondroplasia
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 02 Jul 2024 According to a Tyra Biosciences media release, company is looking forward to submit IND in the second half of this year to support our planned Phase 2 study in pediatric achondroplasia.
  • 01 Feb 2024 According to a Tyra Biosciences media release, company announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to TYRA-300 for the treatment of achondroplasia.
  • 22 Dec 2023 According to a Tyra Biosciences media release, the company has received feed back from FDA and plans to submit an Investigational New Drug (IND) application to the US FDA in the second half of 2024 for the initiation of the Phase 2 study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top